Skip to contentA
Axim Biotechnologies, Inc.
A
AXIMAxim Biotechnologies, Inc. Q2 2014 · 10-Q
Revenue$0.00$0.00−100.0% vs Q2 2013 Net Income-$44.77K-$44.77KN/M vs Q2 2013 EPS Diluted$0.00$0.00— vs Q2 2013 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Axim Biotechnologies, Inc. · CIK 1514946 · Engraved from SEC EDGAR
ended Jun 30, 2014 · filed Aug 19, 2014 · 50 d after period end